TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34344233

Group type: EXPERIMENTAL
Intervention: Good-quality video
Number of subjects: 388

Group type: COMPARATOR
Intervention: Poor-quality video
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Good-quality high cholesterol video first
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: SDM Process score
Number of subjects: 388

Group type: COMPARATOR
Intervention: High cholesterol model
Number of subjects: 388

Group type: COMPARATOR
Intervention: Colorectal cancer model
Number of subjects: 388
Study: 32156534

Group type: EXPERIMENTAL
Intervention: Organic Zinc (Zn) 20 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Organic Zinc (Zn) 40 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Organic Copper (Cu) 12.5 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Organic Zinc (Zn) 60 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Organic Copper (Cu) 25 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Organic Copper (Cu) 37.5 mg/kg DM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of Zn 60 + Cu 37.5 mg/kg DM
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (basal diet without mineral supplementation)
Number of subjects: 40
Study: 35084071

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 35 or 70 mg + exposure therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo + exposure therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) + exposure therapy
Number of subjects: 100
Study: 33934463

Group type: EXPERIMENTAL
Intervention: Allocation to the most densely populated cities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random allocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allocation based on the ratio of patients to ICU personnel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prioritisation in terms of intrahospital mortality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prioritisation of younger populations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prioritisation in terms of population mortality
Number of subjects: 0
Study: 32011017

Group type: EXPERIMENTAL
Intervention: Environmental exposures (including socio-economic status, water source, sanitary facility, domestic animals, maternal characteristics, season, antibiotic use, and delivery mode)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Season of stool sample collection
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Type of water source and maternal education
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 631
Study: 35787135

Group type: EXPERIMENTAL
Intervention: GCSF (300 μg subcutaneously administered two days after IUI)
Number of subjects: 0
Study: 32798161

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) membranes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Deproteinized bovine bone and a resorbable collagen membrane
Number of subjects: 27
Study: 35846327

Group type: EXPERIMENTAL
Intervention: Progesterone + Metformin
Number of subjects: 219

Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 219
Study: 33044039

Group type: EXPERIMENTAL
Intervention: Irritrol with Er,Cr:YSGG laser
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: QMix with diode laser
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: QMix with Er,Cr:YSGG laser
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: QMix with diode and Er,Cr:YSGG lasers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser activation
Number of subjects: 90
Study: 32060156

Group type: EXPERIMENTAL
Intervention: Standard SWMS care plus a targeted prescribing pathway for LIRA 3 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: Standard SWMS care
Number of subjects: 384
Study: 616379759

Group type: EXPERIMENTAL
Intervention: Palliative care-led meetings
Number of subjects: 0
Study: 34895109

Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus GG DSM 33156
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 32064727

Group type: EXPERIMENTAL
Intervention: Email alert group (n = 362)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Control group (n = 344)
Number of subjects: 706
Study: 34153808

Group type: EXPERIMENTAL
Intervention: Corrective exercises and neuromuscular electrical stimulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Corrective exercises and sham neuromuscular electrical stimulation
Number of subjects: 72
Study: 34669192

Group type: EXPERIMENTAL
Intervention: Strengths-based, culturally responsive family intervention
Number of subjects: 248
Study: 32893128

Group type: EXPERIMENTAL
Intervention: Macrogol one sachet in the morning for two days prior to surgery
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Macrogol one sachet, morning and evening of the day prior to surgery
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 34984549

Group type: EXPERIMENTAL
Intervention: Nutrition Education and Counseling (NEC) program
Number of subjects: 468

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 468
Study: 33823150

Group type: EXPERIMENTAL
Intervention: Revealed group (selective planned deliveries based on maternal levels of placental growth factor)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Concealed group (expectant management under usual care)
Number of subjects: 178
Study: 36130755

Group type: EXPERIMENTAL
Intervention: RTX+LD CYC
Number of subjects: 100

Group type: COMPARATOR
Intervention: RTX
Number of subjects: 100
Study: 33412557

Group type: EXPERIMENTAL
Intervention: Nifurtimox 10–20 mg/kg/day (aged <12 years) or 8–10 mg/kg/day (aged ≥12 years) for 60 days
Number of subjects: 330

Group type: COMPARATOR
Intervention: Nifurtimox for 30 days plus placebo for 30 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nifurtimox for 60 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nifurtimox for 30 days
Number of subjects: 330
Study: 32848380

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 µg combination therapy
Number of subjects: 506

Group type: COMPARATOR
Intervention: tiotropium 5 µg
Number of subjects: 506

Group type: COMPARATOR
Intervention: olodaterol 5 µg
Number of subjects: 506

Group type: COMPARATOR
Intervention: tiotropium/olodaterol 5/5 µg
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Number of subjects: 506
Study: 36114137

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6262
Study: 32916655

Group type: EXPERIMENTAL
Intervention: Fast Tempo (FT) hexagonal‐barbell deadlifts
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow Tempo (ST) hexagonal‐barbell deadlifts
Number of subjects: 8
Study: 35301982

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy
Number of subjects: 607

Group type: COMPARATOR
Intervention: Ureteroscopic stone treatment
Number of subjects: 607
Study: 32342158

Group type: EXPERIMENTAL
Intervention: Full percutaneous interbody fusion technique with posterior stabilization using rods and screws and an 8-mm-width intradiscal cage
Number of subjects: 79
Study: 35930976

Group type: EXPERIMENTAL
Intervention: High-flow normobaric oxygen (NBO) by Venturi mask (FiO2 50%, flow 15 L/min) for 6 hours
Number of subjects: 87

Group type: COMPARATOR
Intervention: Routine low-flow oxygen supplementation by nasal cannula (flow 3 L/min) for 6 hours
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: High-flow normobaric oxygen (NBO)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Routine low-flow oxygen supplementation by nasal cannula
Number of subjects: 87
Study: 33610902

Group type: COMPARATOR
Intervention: Dietary crude protein (CP) level at 17.5%
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary crude protein (CP) level at 16.5%
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary crude protein (CP) level at 15.5%
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary crude protein (CP) level at 14.5%
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary crude protein (CP) level at 13.5%
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Dietary crude protein (CP) levels
Number of subjects: 720
Study: 32677170

Group type: EXPERIMENTAL
Intervention: Doublebase gel (DBG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myribase gel (MBG)
Number of subjects: 0
Study: 35219776

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice a day) with RDI >98%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice a day) with RDI 90%-98%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice a day) with RDI <90%
Number of subjects: 185
Study: 32642957

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) ketamine (30 and 50 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 35986383

Group type: EXPERIMENTAL
Intervention: Wedge-cut Weil osteotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Flat-cut Weil osteotomy
Number of subjects: 80
Study: 34330204

Group type: EXPERIMENTAL
Intervention: Brief Mindful Hypnosis (BMH)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cognitive Training (CT)
Number of subjects: 55
Study: 33405182

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB) in patients with hiatus hernia (HH)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB) in patients with preoperative GORD on PPI
Number of subjects: 89
Study: 36169690

Group type: EXPERIMENTAL
Intervention: SP+DS method
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: ACR-TIRADS combined with Kwak-TIRADS in parallel
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: C-TIRADS combined with EU-TIRADS in serial
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: DS for inconsistently diagnosed nodules
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Kwak-TIRADS
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: EU-TIRADS
Number of subjects: 795
Study: 34020856

Group type: EXPERIMENTAL
Intervention: Long-form TCR data accuracy rates
Number of subjects: 700
Study: 32895283

Group type: EXPERIMENTAL
Intervention: Description-based risk education intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experience-based risk education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both interventions (description-based and experience-based)
Number of subjects: 0
Study: 35842700

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including peer education camps, menstrual hygiene laboratories, mother's outreach sessions, community meetings, and improvements to school WASH facilities over a three-month period.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (25 schools without the intervention).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multi-component intervention.
Number of subjects: 50
Study: 33246021

Group type: EXPERIMENTAL
Intervention: Alpelisib (300 mg/day) plus fulvestrant (500 mg every 28 days and once on day 15)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Alpelisib-fulvestrant
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo-fulvestrant
Number of subjects: 341
Study: 35879534

Group type: EXPERIMENTAL
Intervention: HL6 measure via text messaging
Number of subjects: 306

Group type: COMPARATOR
Intervention: HL6 measure via online survey
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Higher HL6 scores
Number of subjects: 306
Study: 34174474

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study: 32586583

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 1240
Study: 35750737

Group type: EXPERIMENTAL
Intervention: Amoxicillin 2 grams preoperatively
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 34836081

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Cervical-SAT reduction
Number of subjects: 278
Study: 32211778

Group type: EXPERIMENTAL
Intervention: Wind turbine noise (WTN) at 32 dB LAEq during sleep nights
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (quiet night)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality
Number of subjects: 50
Study: 35750588

Group type: EXPERIMENTAL
Intervention: 5-minute scripted phone call from a physician 3–4 days after embryo transfer
Number of subjects: 231

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 231
Study: 33988549

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Neck dissection
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High-risk features
Number of subjects: 93
Study: 36250662

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Rilonacept (bailout)
Number of subjects: 84
Study: 33217822

Group type: EXPERIMENTAL
Intervention: Metabolic B‐SES
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 33010323

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ciclopiroxolamine 1% cream
Number of subjects: 114
Study: 33002553

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg/day with Metformin 1000 mg/day
Number of subjects: 80
Study: 36309760

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) starting on postoperative day (POD) 1 at 200-300 ml/day, increased to 400-600 ml/day on POD 2, depending on surgeon's decision from POD 3.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peripheral Parental Nutrition (PPN) delivered after surgery.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both groups start oral feeding on POD 3.
Number of subjects: 320
Study: 34328151

Group type: EXPERIMENTAL
Intervention: 500 mg of Salmon milt peptide (SMP) administered continuously or as a single dose for one week
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 14
Study: 36164011

Group type: EXPERIMENTAL
Intervention: Rusfertide (10-120 mg weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rusfertide (40 mg SQ twice weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rusfertide interruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinitiating rusfertide
Number of subjects: 0
Study: 33119898

Group type: EXPERIMENTAL
Intervention: Venetoclax plus azacitidine (AZA; 75 mg/m2; days 1-7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine (DEC; 20 mg/m2; days 1-5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venetoclax plus azacitidine (AZA) and decitabine (DEC)
Number of subjects: 0
Study: 32771105

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy for peanut allergy
Number of subjects: 0
Study: 35460273

Group type: EXPERIMENTAL
Intervention: Endoscope-assisted post-auricular sulcus incision
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional Blair 'S' incision
Number of subjects: 45
Study: 34499961

Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test, TSST)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 51
Study: 35445687

Group type: EXPERIMENTAL
Intervention: Latin dance program (4-month duration, followed by a 4-month maintenance program)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 333
Study: 32578472

Group type: EXPERIMENTAL
Intervention: 7-day intake of NZBC extract (600 mg containing 210 mg of anthocyanins)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 14-day intake of NZBC extract (600 mg containing 210 mg of anthocyanins)
Number of subjects: 16
Study: 33058991

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 429

Group type: COMPARATOR
Intervention: Liberal oxygen therapy
Number of subjects: 429
Study: 34718239

Group type: EXPERIMENTAL
Intervention: Active-phase UC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remission-phase UC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Irritable bowel syndrome)
Number of subjects: 30
Study: 33112049

Group type: EXPERIMENTAL
Intervention: Hazelnut oil containing 24.2 mg kg‐1 2‐MCPD and 54.5 mg kg‐1 3‐MCPD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Background excretion before exposure
Number of subjects: 12
Study: 32282696

Group type: EXPERIMENTAL
Intervention: HAL‐RAR with Doppler US navigation
Number of subjects: 204

Group type: COMPARATOR
Intervention: HAL with manual HA detection and mucopexy
Number of subjects: 204
Study: 32888828

Group type: EXPERIMENTAL
Intervention: Geranium aromatherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 34192759

Group type: EXPERIMENTAL
Intervention: Theracal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dycal
Number of subjects: 60
Study: 35285428

Group type: EXPERIMENTAL
Intervention: Early intervention (eight sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 33546610

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) combined with sit-to-stand (STS) exercises for 12 weeks
Number of subjects: 0
Study: 616791867

Group type: EXPERIMENTAL
Intervention: TAS‐102 35 mg/m² orally twice daily after meals on days 1 through 5 and 8 through 12 of each 28‐day cycle (n = 534)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (n = 266)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: TAS‐102 35 mg/m²
Number of subjects: 800
Study: 33749531

Group type: EXPERIMENTAL
Intervention: Beck Scale for Suicide Ideation (BSS)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Suicidal Behaviors Questionnaire‐Revised (SBQ‐R)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Self‐Injurious Thoughts and Behaviors Interview‐Short Form (SITBI‐SF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Inconsistent Responders
Number of subjects: 141
Study: 34560686

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (n = 265)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Direct laryngoscopy (n = 269)
Number of subjects: 501
Study: 33925049

Group type: EXPERIMENTAL
Intervention: 50% whole grain cereals with 12 g sugar (50-WG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0% whole grain cereals with 24 g sugar (0-WG)
Number of subjects: 43
Study: 32065303

Group type: EXPERIMENTAL
Intervention: BCG followed by TFV
Number of subjects: 30

Group type: COMPARATOR
Intervention: TFV alone
Number of subjects: 30
Study: 36030401

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (three 50-min sessions each week at 70% maximal power for 8 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17

Group type: COMPARATOR
Intervention: No-exercise control period
Number of subjects: 17
Study: 33788461

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion combined with western medication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple western medication (alendronate sodium tablet, calcium carbonate, vitamin D3 tablet)
Number of subjects: 60
Study: 33437034

Group type: EXPERIMENTAL
Intervention: Counselors communicating the essence of uncertainty and providing information
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Comprehensive information
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Counselor using information providing responses
Number of subjects: 224
Study: 32376347

Group type: EXPERIMENTAL
Intervention: VSI (video + manikin)
Number of subjects: 1325

Group type: COMPARATOR
Intervention: mApp (video, no manikin)
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Comparison of mApp to VSI
Number of subjects: 1325
Study: 34902838

Group type: EXPERIMENTAL
Intervention: Circular Tandem Walk Test (CTWT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CTWT time to perform ≥ 14.6 seconds
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CTWT with ≥ two error scores
Number of subjects: 89
Study: 33404668

Group type: EXPERIMENTAL
Intervention: Osgood Schlatter disease (OSD) group
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (without OSD)
Number of subjects: 171
Study: 34252203

Group type: EXPERIMENTAL
Intervention: 8 L of balanced hypotonic electrolyte supplement
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1 to 3 L of water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 8 L of balanced hypotonic electrolyte supplement with 42K
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Electrolyte supplementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Radiotracer 24Na+ and 42K+
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post-exercise Na+ and K+ levels
Number of subjects: 8
Study: 35867777

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tendon needling (TN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo needling (PN)
Number of subjects: 60
Study: 34682309

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group (n = 18)
Number of subjects: 82
Study: 32618385

Group type: EXPERIMENTAL
Intervention: Weight-management programme (WW) for 12 weeks
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Weight-management programme (WW) for 52 weeks
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Brief intervention (BI; self-help booklet)
Number of subjects: 1267
Study: 36050227

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 4796

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study: 33863751

Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0